Table 2

 Clinical and laboratory features of anti-CCP2 and/or anti-CCP1 positive patients with AIH-1

CaseSexAgeRheumatologic featuresRFNOSCCP2 reactivity (U/ml)CCP1 reactivity
ANA, anti-nuclear antibodies; CCP, cyclic citrullinated peptide; F, female; M, male; NOS, non-organ specific antibodies; NT, not tested; RF, rheumatoid factor; SMA, anti-smooth muscle antibodies; –, negative serum.
*Citrulline-independent.
†Completely citrulline-specific.
‡Citrulline-preferred.
1M17NoneNegativeANA + SMA<25Positive*
2F16NoneNegativeSMA<25Positive*
3F72NoneNegativeANA + SMA34*Positive*
4F23NoneNegativeSMA41Positive*
5F57PolyarthritisNegativeANA135*Positive*
6F26NoneNegativeSMA63*Positive*
8F35NoneNegativeANA + SMA26*Positive*
9F20NoneNegativeSMA<25Positive*
10F16NoneNegativeSMA509Positive*
11F76Mild polyarthritisNegativeANA237Positive
12F65Palindromic rheumatismPositiveSMA332Positive
14F38NoneNegativeANA + SMA<25Positive*
15F69Sjögren’s syndrome; polyarthritisPositiveANA135Negative
22F38NoneNegativeNeg<25Positive*
31F49NoneNegativeANA<25Positive*
32M73PolyarthritisPositiveANA81NT
42F32NonePositiveANA + SMA36*NT
55F36NonePositiveANA25NT